Feliqs Corporation
Building a Unique Drug Discovery Platform to Detect ferroptosis
ferroptosis, newly reported in 2012, is cell death caused by the accumulation of lipid peroxides. In recent years, ferroptosis has been reported to be associated with many diseases such as cancer, Ischemia-reperfusion injury, and neurological disorders, and is being actively studied as a new drug discovery target. Feliqs, a startup from Kyushu University, has built a unique drug discovery screening platform using probes that detect lipid radical that lead to ferroptosis, and is proceeding with research and development as a unique pipeline.
- Establishment Date
- February 2019
- Business
- Development of new therapeutic drugs using our original drug discovery screening platform
- CEO
- Representative DirectorKenichiro Ken-ichiro Kuninobu
KII’s Perspective
We have a drug discovery screening platform that focuses on ferroptosis, a newly discovered type of programmed cell death, and we expect to provide multiple new therapeutic drugs in areas with large unmet medical needs in existing treatments.
KII growth support
Financing assistance, Business strategy support, Business alliance support, Recruitment support, Public relations support, Appointment of directors
